DarioHealth Corp.
NASDAQ:DRIOMedical - Diagnostics & Research
-$0.12 today
- Market cap
- $50.27M
- Beta
- 1.08
- P/E (TTM)
- 5.5
- EPS (TTM)
- $1.26
Volume 0.01M
Average 0.01M
DRIO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
DarioHealth Corp.NASDAQ: DRIO
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables declines year over year
Q1 FY2026 accounts receivables of $194K fell 84.2% year over year, behind the -73.6% change in trailing-twelve-month accounts receivables. Sequentially, it fell 71.7% from the prior quarter.
Context
- Accounts receivables amounted to 11.8% of revenue in FY2025, up 5.9 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -84.2% toward the trailing-twelve-month pace of -73.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 2.64M USD
- Year-over-year change
- +65.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.64M | +65.3% |
| FY2024 | 2024-12-31 | 1.6M | -43.6% |
| FY2023 | 2023-12-31 | 2.84M | +155.5% |
| FY2022 | 2022-12-31 | (5.11M) | -1292.1% |
| FY2021 | 2021-12-31 | (367K) | — |
Accounts Receivables vs competitors
How DRIO compares with its peers on the latest reported figures
- DRIO's LTM Mar 2026 accounts receivables of $1.61M is the 10th largest of the 11 companies compared; the peer median is $1.84M.
- Its year-over-year change of -73.6% is the 8th highest of 11, against a peer median of +62.1%.
- Accounts receivables amounts to 7.6% of revenue for DRIO, versus a peer median of 1.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.16M | -39169.2% | — | 20.5% | |
| LTM Mar 2026 | $9.02M | +328.9% | — | 10.3% | |
| LTM Mar 2026 | $5.5M | -46.6% | — | 0.8% | |
| LTM Mar 2026 | $5.26M | +166.0% | -38.3% | 0.6% | |
| LTM Mar 2026 | $4.32M | +141.8% | — | 0.5% | |
| LTM Mar 2026 | $3.3M | -17.5% | -7.0% | 0.4% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $2.59M | -415.9% | — | 26.6% |
| LTM Mar 2026 | $2.3M | -89.7% | — | 0.7% | |
| LTM Mar 2026 | $2.3M | +273.6% | — | 1.4% | |
| LTM Mar 2026 | $1.61M | -73.6% | — | 7.6% | |
| LTM Mar 2026 | $1.38M | +207.1% | — | 75.4% | |
| Peer median (excluding DRIO) | $1.84M | +62.1% | -22.6% | 1.1% | |
Competitors are the stored peer set for DRIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (76.76M) | (62.19M) | (59.43M) | (42.75M) | (41.71M) |
| Depreciation & Amortization | 4.46M | 4.72M | 4.99M | 7.43M | 2.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 24.97M | 16.98M | 19.7M | 15.8M | 9.37M |
| Change in Working Capital | (2.57M) | (10.9M) | 4.07M | (2.47M) | 2.21M |
| Accounts Receivables | (367K) | (5.11M) | 2.84M | 1.6M | 2.64M |
| Inventory | (2.23M) | (1.73M) | 2.89M | 308K | 437K |
| Accounts Payables | 1.08M | (2.79M) | (1.19M) | (496K) | (122K) |
| Other Working Capital | (1.06M) | (1.28M) | (464K) | (3.88M) | (752K) |
| Other Non-Cash Items | (503K) | 3.56M | 288K | (16.57M) | 1.37M |
| Operating Cash Flow | (50.41M) | (47.85M) | (30.38M) | (38.56M) | (25.94M) |
| Capital Expenditures | (261K) | (573K) | (584K) | (138K) | (142K) |
| Acquisitions (Net) | (7.47M) | 0 | 0 | (8.8M) | 0 |
| Purchases of Investments | 0 | 0 | (5M) | 0 | (4.2M) |
| Sales of Investments | 0 | 0 | 5.03M | 0 | 0 |
| Other Investing Activities | (400K) | (131K) | 0 | 0 | 0 |
| Investing Cash Flow | (8.13M) | (573K) | (547K) | (8.93M) | (4.34M) |
| Debt Repayment | 0 | 23.79M | 1.77M | 0 | 185K |
| Common Stock Issued | 64.88M | 38.29M | 1.61M | 0 | 24.13M |
| Common Stock Repurchased | 0 | (134K) | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 889K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 65.77M | 61.94M | 18.25M | 38.53M | 24.31M |
| Effect of Forex Changes | 0 | 0 | 0 | (68K) | 9K |
| Net Change in Cash | 7.22M | 13.52M | (12.67M) | (9.03M) | (5.96M) |
| Free Cash Flow | (50.67M) | (48.42M) | (30.96M) | (38.7M) | (26.08M) |
DarioHealth Corp.
NASDAQ:DRIO
Intrinsic Alpha fair value
Locked
Current Price
$5.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.